Evaluation and Adaptation of the HEMOTAG System for Heart Failure Patients Outside Hospital Settings to Reduce Readmissions

What this Trial Is About

Researchers are evaluating the HEMOTAG system to help manage heart failure patients outside of traditional medical settings. The goal is to reduce hospital readmissions by testing, adapting, and validating this system for use by patients in their everyday environments. This study focuses on short-term outcomes for people with heart failure, assessing how well the system works in real-life situations compared to standard care. Participants are randomly assigned to one of two groups standard care alone or standard care combined with the HEMOTAG system. The study observes participants over 30 days for hospital readmission rates and monitors related outcomes up to six months. The HEMOTAG system, considered a diagnostic test, is being assessed as an additional tool alongside usual treatments to evaluate its impact on heart failure management. During the study, participants will have their health monitored regularly, including tracking hospital readmissions due to heart failure and any skin irritation from using the HEMOTAG device during the first 30 days. Researchers also measure time to readmission, total days lost to hospitalization, and all-cause mortality up to six months after discharge. The study includes assessments through medical records and patient monitoring to understand how the system affects short-term health outcomes and safety over the monitoring periods.

HEMOTAG® Assessment for Short-term Outcomes of Heart Failure